Novo touts comparative data on modern insulin Degludec; Glaxo invests in Theravance;

 @FierceBiotech:  Novartis CEO outlines a winning drug development strategy. News | Follow @FierceBiotech 

 @JohnCFierce: Molecular Partners AG reports it got a $420M deal with Allergan on opthalmic program. $45M upfront. Story | Follow @JohnCFierce

> Denmark's Novo Nordisk reports that its modern insulin Degludec, a once-daily therapy, outperformed Sanofi's rival once-daily Lantus in a comparative study. Novo reported that they found that Degludec patients benefited from a lower rate of overall confirmed blood sugar and a lower rate of nocturnal confirmed blood sugar. Report

> GlaxoSmithKline is investing $6.7 million in Theravance, a biotech company it is partnered with. Story

> Echo Therapeutics says it has relocated its corporate headquarters from Franklin, MA to Philadelphia, PA. Echo release

Pharma News

@FiercePharma: Is a Bayer 'merger of equals' in the stars? Story | Follow @FiercePharma

> Garnier pledges active role on Actelion board. News

> J&J, generics makers to revamp children's Tylenol products. Report

> Everest expedition doctor packs Viagra for climbers. Article

> Roche-funded eye study highlights Avastin risks. Story

> GSK poised to settle another 1,000 Avandia suits. News

Vaccines News

> Gates gives $8.9M to fund new malaria vaccine approach. Story 

> Sweden's Isconova buys Nordic Vaccine. News 

> Government funds Ebola, Marburg vaccine. Report 

> OncoPep vax aims to stop multiple myeloma before it starts. Article

> UCF Professor wins Gates grant for needle-free vaccines. Story 

Manufacturing News

> Specialty distributor skillset quantified. News

> Drug shortages suggest business niche. Article

> QA neglect jeopardizes Ranbaxy's future revenue. Story

> Novasep, Solvias ingenuity trump offshoring. Report

> Expert hints open standards may help Pfizer's PAT. News

And Finally... Researchers say that in most cases new drugs are approved by the FDA even though there is no relevant comparative data available for payers on how their performance stacks up against existing meds. Story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.